



Advances in Insulin Therapy: Improving Glycemic Control in Modern Diabetes Care

Ethan Brooks*

Department of Endocrinology, Westbridge University, Manchester, United Kingdom

DESCRIPTION

Diabetes mellitus is one of the most common chronic metabolic disorders affecting people across all age groups. It develops when the body is unable to produce sufficient insulin or cannot effectively utilize the insulin that is produced. This leads to elevated blood glucose concentrations, which over time may contribute to complications involving the cardiovascular system, kidneys, eyes, nerves, and other organs [1]. Since the discovery of insulin more than a century ago, its clinical use has transformed diabetes management and significantly increased the life expectancy of millions of individuals worldwide. Continuous improvements in insulin formulations, delivery methods, and glucose monitoring technologies have provided healthcare professionals with greater flexibility in designing treatment strategies that meet individual patient needs [2].

Insulin is a peptide hormone synthesized by the beta cells located within the islets of Langerhans in the pancreas. The hormone consists of two amino acid chains connected by disulfide bonds and is released into the bloodstream when blood glucose levels rise, particularly after food consumption [3]. Once secreted, insulin binds to receptors present on the surface of various body cells, allowing glucose to enter muscle and adipose tissue where it can be used for energy production or stored for future use. Simultaneously, insulin decreases glucose production by the liver while encouraging glycogen synthesis. Beyond carbohydrate metabolism, insulin also influences fat storage and protein synthesis, making it an essential regulator of overall metabolism [4].

Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, leading to an absolute deficiency of insulin. Individuals with this condition require lifelong insulin replacement because the body cannot produce the hormone naturally. In contrast, Type 2 diabetes usually develops due to insulin resistance combined with a gradual decline in insulin secretion [5]. Lifestyle modifications and oral glucose-lowering medications may initially provide adequate blood glucose control

for many people with Type 2 diabetes, but insulin treatment often becomes necessary as pancreatic function declines over time. Gestational diabetes, which develops during pregnancy, may also require insulin therapy when lifestyle measures alone do not adequately control maternal blood glucose levels [6].

The availability of different insulin preparations has allowed clinicians to closely mimic natural insulin secretion. Rapid-acting insulin analogues begin working within minutes after injection and are commonly administered immediately before meals to control postprandial glucose elevations [7]. Short-acting human insulin has a slightly delayed onset and generally requires administration approximately thirty minutes before eating. Intermediate-acting insulin provides longer glucose control and has traditionally been used as basal insulin in many treatment regimens. Long-acting and ultra-long-acting insulin analogues offer extended glucose-lowering effects with relatively stable activity throughout the day and night, reducing fluctuations in blood glucose and lowering the frequency of injections for many patients [8].

Selecting an appropriate insulin regimen depends on multiple clinical considerations including age, type of diabetes, lifestyle, meal patterns, renal function, and individual treatment goals. Basal insulin therapy supplies a continuous level of insulin throughout the day to regulate fasting glucose concentrations. Mealtime insulin is added to manage increases in blood glucose following food intake. The combination of basal and bolus insulin provides physiological replacement for individuals with Type 1 diabetes and many patients with advanced Type 2 diabetes. Premixed insulin formulations, which contain fixed proportions of rapid- or short-acting insulin combined with intermediate-acting insulin, may be suitable for patients seeking a simplified dosing schedule with fewer daily injections [9].

Accurate insulin administration is essential for maintaining stable glucose control. Modern insulin pens have become increasingly popular because they are portable, simple to operate, and allow precise dose adjustments. Disposable and reusable pen devices improve convenience and may encourage

Correspondence to: Ethan Brooks, Department of Endocrinology, Westbridge University, Manchester, United Kingdom. E-mail: ethan.brooks.wbu@medmail.org

Received: 19-May-2026, Manuscript No. DCRS-26-32158; **Editor assigned:** 21-May-2026, Pre QC No. DCRS-26-32158 (PQ); **Reviewed:** 04-Jun-2026, QC No. DCRS-26-32158; **Revised:** 11-Jun-2026, Manuscript No. DCRS-26-32158 (R); **Published:** 19-Jun-2026, DOI: 10.35841/2572-5629.26.11.288

Citation: Brooks E (2026). Advances in Insulin Therapy: Improving Glycemic Control in Modern Diabetes Care. Diabetes Case Rep. 11:288.

Copyright: © 2026 Brooks E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

better adherence compared with traditional syringes. Continuous subcutaneous insulin infusion through insulin pumps offers another option for selected patients. Pumps deliver a constant basal rate of insulin throughout the day while allowing additional doses before meals. These devices provide greater flexibility in daily activities and may reduce blood glucose variability when combined with careful glucose monitoring [10].

CONCLUSION

Insulin continues to play an essential role in the management of diabetes across diverse patient populations. Careful selection of insulin formulations, individualized treatment planning, regular glucose monitoring, patient education, and consistent follow-up contribute to effective blood glucose management and reduction of diabetes-related complications. Continuous scientific progress has expanded therapeutic options, allowing clinicians to provide safer and more convenient treatment approaches. With ongoing research and improved clinical practice, insulin therapy is expected to remain an indispensable component of comprehensive diabetes care while supporting better quality of life for individuals living with this chronic condition.

REFERENCES

1. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. *Nat Rev Mol Cell Biol.* 2021;22(11):751-771.
2. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. *Nat Rev Endocrinol.* 2014;10(5):293-302.
3. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. *Am J Physiol.* 1979;1.
4. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet.* 2010;42(2):105-116.
5. Williamson A, Norris DM, Yin X, Broadaway KA, Moxley AH, Vadlamudi S, et al. Genome-wide association study and functional characterization identifies candidate genes for insulin-stimulated glucose uptake. *Nat Genet.* 2023;55(6):973-983.
6. Chen J, Varshney A, Corbin LJ, Luan J, Wu Y, Zhang X et al. The trans-ancestral genomic architecture of glycemic traits. *Nat Genet.* 2021;53(6):840-860.
7. Oliveri A, Rebernick RJ, Kuppa A, Pant A, Chen Y, Du X, et al. Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank. *Nat Genet.* 2024;56(2):212-221.
8. Udler, M. S. Dynamic measures of insulin action identify genetic determinants of dysglycemia. *Nat Genet.* 2023;55(6):905-907.
9. Rosoff DB, Mavromatis LA, Bell AS, Wagner J, Jung J, Marioni RE, et al. Multivariate genome-wide analysis of aging-related traits identifies novel loci and new drug targets for healthy aging. *Nat Aging.* 2023;3(8):1020-1035.
10. Baselmans BM, Jansen R, Ip HF, van Dongen J, Abdellaoui A, van de Weijer MP, et al. Multivariate genome-wide analyses of the well-being spectrum. *Nat Genet.* 2019;51(3):445-451.